NTLA vs HRMY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
HRMY Captures Institutional Edge (3โ1 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin, Options & Structure while NTLA counters with relative strength in Momentum & Technical. Fundamentally, NTLA trades at N/M Forward P/E with -826.0% operating margin (-48.0% YoY revenue) versus HRMY at 5.6x Forward P/E and 22.2% operating margin (+12.3% YoY). In options structure, NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro) against HRMY sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NTLA Revenue | HRMY Revenue | NTLA Op. Margin | HRMY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $30M | N/A | -298.6% | N/A | NTLA |
| FY2019 | $40M | $10M | -246.8% | -2433.8% | NTLA |
| FY2020 | $60M | $160M | -235.5% | 10.6% | HRMY |
| FY2021 | $30M | $310M | -810.4% | 28.7% | HRMY |
| FY2022 | $50M | $440M | -879.0% | 27.4% | HRMY |
| FY2023 | $40M | $580M | -1420.5% | 33.0% | HRMY |
| FY2024 | $60M | $710M | -923.1% | 26.7% | HRMY |
| FY2025 | $70M | $870M | -651.7% | 24.0% | HRMY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NTLA | HRMY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $2.0B | Larger Scale | HRMY |
| Trailing P/E Ratio Valuation | N/M | 11.2x | Lower Multiple | HRMY |
| Forward P/E Ratio Valuation | N/M | 5.6x | Lower Multiple | HRMY |
| Revenue Growth (YoY) Growth | -48.0% | +12.3% | Higher Growth | HRMY |
| Operating Margin (TTM) Profitability | -826.0% | 22.2% | Higher Margin | HRMY |
| Net Profit Margin Profitability | 0.0% | 18.1% | Higher Margin | HRMY |
| Return on Equity (ROE) Capital Efficiency | -62.6% | 18.7% | Higher ROE | HRMY |
| 52-Week Range Position Momentum | 20% ($8โ$18) | 41% ($26โ$43) | Stronger Trend | HRMY |
| Beta / 30D Volatility Risk Regime | 2.30ฮฒ ยท 87% Vol | 0.60ฮฒ ยท 45% Vol | Lower Realized Risk | HRMY |
| Unified Institutional Score Composite Signal | 49.9 / 100 (HOLD) | 57.1 / 100 (HOLD) | Higher Composite | HRMY |